Right Drug

Coxibs were developed and approved for the chronic treatment of pain and inflammation.  Use of high doses of coxibs to effectively treat cancer has been limited due to potential safety issues in combination with standard-of-care (SOC) chemotherapeutics and targeted therapy.  Euclicoxibs™ are designed to both increase anti-cancer potency and safely reach higher doses/exposures required for maximal anti-cancer effectiveness while mitigating side-effects with combination therapies.  Euclicoxibs™ are expected to be the right drugs to use in combination with SOC to treat refractory cancers that are driven by COX-2 and are sensitive to COX-2 inhibition.